Prosocial Effects of MDMA (PEM)

This early Phase I crossover trial (n=34) investigates the effects of familiarity on the prosocial effects of MDMA (100mg) in social interactions. The study aims to test the hypothesis that MDMA produces greater prosocial effects when administered in the presence of a familiar person compared to an unfamiliar one.

MDMA has shown promise in treating PTSD when combined with psychotherapy, with the patient-therapist relationship considered crucial. The study involves four sessions where participants receive MDMA (100mg) or a placebo, engaging in a 15-minute conversation with either a familiar or unfamiliar person. The trial commenced on July 21, 2023, and is estimated to be completed by June 2024. Hanna Molla can be contacted for study-related information.

Topic PTSD
Compound MDMA Placebo
Country United States of America
Visit trial
Status Recruiting
Results Published No
Start date 21 July 2023
End date 30 June 2024
Phase Phase I
Design Blinded
Type Interventional
Generation First
Participants 34
Sex All
Age 18- 35
Therapy Yes

Trial Details

In this study, the aim is to test the hypothesis that MDMA produces greater prosocial effects when administered in the presence of a familiar, compared to an unfamiliar, person

NCT Number NCT05948683

Sponsors & Collaborators

University of Chicago
Research with psychedelics is taking place at the Human Behavioral Pharmacology Lab at the University of Chicago.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.
?>